Actelion Pharmaceuticals Ltd / Actelion to discuss its specialty immunology pipeline compounds . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Dear member of the investment community

Actelion has announced that it is accelerating its clinical development efforts in the field of immunological disorders. An investor conference call & webcast will be held at 13.00 hrs, CEST to offer the opportunity to discuss the rational for this strategic decision.

Date/Time:

     
16 April 2015 13.00 hrs - 14.00 hrs Basel (CEST)
  12.00 hrs - 13.00 hrs UK (BST)
  07.00 a.m. - 08.00 a.m. US (EDT)

 

Conference Call Connect #:

Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.

       
Dial: Europe: +41 (0) 44 580 00 77
  UK: +44 (0) 203 367 94 59
  US: +1 866 907 59 28

 

Participant's mode:

Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.

Webcast Access:

Webcast participants should visit the Actelion website http://www.actelion.com:
http://www.actelion.com/ 10-15 minutes before the conference is due to start. 

Participant's mode:

Listen-Only           

Webcast Replay:

The archived Investor Webcast will be available for replay through http://www.actelion.com:
http://www.actelion.com//  approximately 60 minutes after the call has ended.  


Invitation PDF:
http://hugin.info/131801/R/1911453/682012.pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire
HUG#1911453

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;